Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease | MicrobiomeTrials← Back to trialsNCT06989359
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-08-28Est. Completion: 2028-12-31
Enrollment target: 45 participants Locations- ADARx Clinical Site, Doral, Florida, United States
- ADARx Clinical Site, Miami, Florida, United States
- ADARx Clinical Site, Pembroke Pines, Florida, United States
- ADARx Clinical Site, Iowa City, Iowa, United States
- ADARx Clinical Site, Shreveport, Louisiana, United States
- ADARx Clinical Site, Shelby, Michigan, United States
- ADARx Clinical Site, Great Neck, New York, United States
- ADARx Clinical Site, Columbus, Ohio, United States
- ADARx Clinical Site, Dakota Dunes, South Dakota, United States
- ADARx Clinical Site, Dallas, Texas, United States
- ADARx Clinical Site, Houston, Texas, United States
- ADARx Clinical Site, Liverpool, New South Wales, Australia
- ADARx Clinical Site, Wollongong, New South Wales, Australia
- ADARx Clinical Site, Sydney, Australia
- ADARx Clinical Site, Woolloongabba, Australia
- ADARx Clinical Site, Hong Kong, Hong Kong
- ADARx Clinical Site, Shatin, Hong Kong
- ADARx Clinical Site, Wŏnju, Gangwon-do, South Korea
- ADARx Clinical Site, Cheonan, South Korea
- ADARx Clinical Site, Daegu, South Korea
- ADARx Clinical Site, Gyeonggi-do, South Korea
- ADARx Clinical Site, Seoul, South Korea
- ADARx Clinical Site, Seoul, South Korea
- ADARx Clinical Site, Seoul, South Korea
- ADARx Clinical Site, Seoul, South Korea
- ADARx Clinical Site, Barcelona, Spain
- ADARx Clinical Site, Madrid, Spain
- ADARx Clinical Site, Seville, Spain
- ADARx Clinical Site, Newcastle upon Tyne, United Kingdom
Other microbiome trials you might be interested in
IgA Nephropathy
This is a phase IIa, multicenter, single-arm, open-label study to evaluate the safety and efficacy of XH-S003 in patient…
Beijing, ChinaCompleted Apr 23, 2026
Immunoglobulin A Nephropathy (IgAN)Complement 3 Glomerulopathy (C3G)IC-MPGN
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults …
Shenzhen, ChinaEst. completion Jul 10, 2028